BMY news, real time BMY stock news, Bristol-Myers Squibb Co news today

News

BMY

53.66

+0.61%

0.33

Leerink Partners Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)

TipRanks · 8h ago

Takeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug

Benzinga · 23h ago

What Bristol-Myers Squibb (BMY)'s Oncology Milestones and Steady Dividend Mean For Shareholders

Simply Wall St · 23h ago

Medicare-negotiated drug prices to halve out-of-pocket costs next year: report

Seeking Alpha · 1d ago

BMY and BNTX Advance New Immunotherapy Bet in First-Line Liver Cancer With ROSETTA HCC-206

TipRanks · 1d ago

White House Readies Drug Price Deals With AbbVie, Novartis, Roche

Benzinga · 1d ago

Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

Dow Jones · 1d ago

Cytokinetics upgraded to Buy at Goldman on odds of ACACIA succeeding

TipRanks · 1d ago

SCHD: This ETF Stinks

Seeking Alpha · 1d ago

These 2 Healthcare Stocks Just Declared Dividend Raises

The Motley Fool · 1d ago

More pharmas expected to sign drug pricing deals with Trump on Friday - report

Seeking Alpha · 2d ago

Bristol-Myers Squibb to Launch Phase 3 Trial for Schizophrenia Drug KarXT in Adolescents

TipRanks · 2d ago

Bristol-Myers Squibb Advances Clinical Trial for BMS-986523 in Oncology

TipRanks · 2d ago

Is Bristol Myers (BMY) Undervalued After Its Recent Share Price Rebound?

Simply Wall St · 2d ago

Harbour BioMed, Bristol Myers More Than $1.1 Bln Deal For Next-Gen Multi-Specific Antibodies

NASDAQ · 2d ago

Analysts Warn That These 3 Stocks Could Sink Further – 12/16/2025

TipRanks · 2d ago

AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen

Benzinga · 3d ago

Bristol-Myers Squibb’s Study on Oral Anticoagulants in Elderly NVAF Patients: Market Insights

TipRanks · 3d ago

BMY Crosses Above Average Analyst Target

NASDAQ · 3d ago

Assessing Bristol Myers Squibb After 16% Rally and New Drug Approvals in 2025

Simply Wall St · 3d ago

Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.

About BMY

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.